OncoSil TGA regulatory update
Filed with ASX · · 2 pages · English
Following the submission to the TGA for inclusion onto the Australian Register of Therapeutic Goods (ARTG), the Company has decided to withdraw the applicationon the basis that the provision of additional clinical data comparing the performance of the OncoSil device directly with other standard therapies is expected to support the application. Nigel Lange, CEO of OncoSil Medical, commented: We app
Earlier from OncoSil Medical
- OncoSil receives regulatory approval from Hong Kong
- Appendix 4C - quarterly
- OncoSil Investor Update
- Appointment of Chief Executive Officer
- OncoSil FY21 half yearly review
Later from OncoSil Medical
- Receipt of $1.077m R&D Tax Incentive Refund
- 2021 AGM CEO Presentation
- PanCO Clinical Study on OncoSil Published in ESMO Open
- OncoSil approved for Innovation Funding (NUB) in Germany
- Half Yearly Report Results
Follow OncoSil Medical into a list and get an email when it puts out news.
Follow OncoSil Medical